Immunotherapy for Parkinson's Disease
•Download as PPTX, PDF•
0 likes•26 views
This Slides Discussed all the immunotherapy for Parkinson's Disease which are in Pre-clinical and clinical trials. It includes both Passive and Active Immunotherapy for PD. PD is the second most common Neurodegenerative disorder after AD.
Report
Share
Report
Share
Recommended
LymeMIND-Abstract_ZUBCEVIK_LARVIE
This document discusses a precision medicine approach to treating Post-Treatment Lyme Disease Syndrome (PTLDS). It uses questionnaires, testing, imaging, and longitudinal data collection to better understand each patient's presentation and develop personalized treatment plans. Examining this data has started to show patterns linking more complex clinical profiles to multiple infections beyond Borrelia or elevated antineuronal antibodies. A precision approach using these diagnostics leads to improved strategies for diagnosis, therapy and rehabilitation for PTLDS patients.
The cell & evolution
The document discusses two research articles about Alzheimer's and Parkinson's diseases. For Alzheimer's, the article discusses how tau proteins jump between neurons using extracellular space and how blocking the protein in this space could help control the spread of Alzheimer's in the brain. For Parkinson's, the article discusses how a mutant LRRK2 gene promotes alpha-synuclein inclusions and how inhibiting this gene could decrease inclusions and pave the way for new treatments. Recognizing the cellular and genetic factors involved in these diseases can help identify causes and potential new treatment targets.
The future of gene therapy used for complex diseases
Gene therapy has made progress but remains limited to rare genetic diseases affecting certain body parts. New generations of gene therapy aim to introduce new functions or allow treatment to be adjusted over time. For brain diseases like epilepsy, gene therapy could directly target affected brain regions to reduce excitatory neuron activity and seizures, offering more precise treatment than existing drugs. For eye diseases, optogenetics may allow a single therapy to treat many mutations causing blindness by transferring lost photoreceptor functions to other retinal cells. These new techniques could help gene therapy reach more diseases.
Targacept- neuronal nicotinic receptors
Targacept is a biopharmaceutical company located in Winston-Salem, NC that was founded in 1997 and has 117 employees. They research disorders of the central nervous system by targeting the nicotinic subtype of acetylcholine neurons in the brain. During their first three years, they were a subsidiary of RJ Reynolds and published many articles on the molecular effects of nicotine and the potential of the neuronal nicotinic receptor as a therapeutic target. They currently have five drug candidates in development for conditions like depression, ADHD, and Alzheimer's, and are conducting a Phase II clinical trial of TC-5619 as an adjunct treatment for cognitive dysfunction in schizophrenia.
Protein ZEB1 and resistance to radiation therapy, and antibodies to damage lungs
The document discusses two studies related to protein interactions that influence disease resistance and treatment outcomes. One study found that the ZEB1 protein can promote breast tumor resistance to radiation therapy by activating DNA damage response pathways. The other found that a type of antibody, IgG2, can allow lung-damaging bacteria to evade destruction by preventing complement protein formation on the bacteria's surface. Both studies provide insight into new treatment resistance mechanisms and potential targets for developing improved therapies.
Sara's rise proposal #2
This document discusses using induced pluripotent stem cells (iPSCs) derived from a patient's own skin cells to generate dopamine-producing neurons for treating Parkinson's disease. Parkinson's involves the death of dopamine neurons in the brain. Previous research using embryonic stem cells in rodents led to tumor formation. The proposed methodology would involve taking skin cells from rodents, generating iPSCs, differentiating them into dopamine neurons, and surgically implanting them into the rodents' brains. This approach could reduce immunorejection risks and provide a new treatment for Parkinson's by replacing lost dopamine neurons. Future studies would assess the safety and effectiveness of this iPSC-based therapy.
molecular biology folding
This document discusses recent discoveries about how certain genes and proteins play roles in various biological processes and diseases. It summarizes two research papers that found: 1) Variants of a gene called AARS can impact brain cells, immune cells, p53 signaling, apoptosis, tumorigenesis and angiogenesis. 2) Poly-peptides encoded by the C9ORF72 gene bind to nucleoli, impair RNA biogenesis, and kill cells, providing insights into neurodegenerative diseases like Alzheimer's and ALS. The student believes these findings could lead to new treatment approaches targeting the underlying causes rather than just symptoms of diseases.
BDSRA 2015 CLN6 Mole
This document summarizes the results of a study testing a gene therapy approach to treat vision loss in a mouse model of Batten disease. The study found that:
1) Photoreceptor function and cells are lost early in Cln6 mice, making it a good model.
2) Treating only photoreceptors with an AAV virus carrying Cln6 did not prevent retinal degeneration, as Cln6 is more highly expressed in inner retinal cells.
3) A new AAV virus was obtained that can target inner retinal cells like bipolar cells, which normally express high Cln6 levels. Future work will treat Cln6 mice with this new virus alone and combined with the original
Recommended
LymeMIND-Abstract_ZUBCEVIK_LARVIE
This document discusses a precision medicine approach to treating Post-Treatment Lyme Disease Syndrome (PTLDS). It uses questionnaires, testing, imaging, and longitudinal data collection to better understand each patient's presentation and develop personalized treatment plans. Examining this data has started to show patterns linking more complex clinical profiles to multiple infections beyond Borrelia or elevated antineuronal antibodies. A precision approach using these diagnostics leads to improved strategies for diagnosis, therapy and rehabilitation for PTLDS patients.
The cell & evolution
The document discusses two research articles about Alzheimer's and Parkinson's diseases. For Alzheimer's, the article discusses how tau proteins jump between neurons using extracellular space and how blocking the protein in this space could help control the spread of Alzheimer's in the brain. For Parkinson's, the article discusses how a mutant LRRK2 gene promotes alpha-synuclein inclusions and how inhibiting this gene could decrease inclusions and pave the way for new treatments. Recognizing the cellular and genetic factors involved in these diseases can help identify causes and potential new treatment targets.
The future of gene therapy used for complex diseases
Gene therapy has made progress but remains limited to rare genetic diseases affecting certain body parts. New generations of gene therapy aim to introduce new functions or allow treatment to be adjusted over time. For brain diseases like epilepsy, gene therapy could directly target affected brain regions to reduce excitatory neuron activity and seizures, offering more precise treatment than existing drugs. For eye diseases, optogenetics may allow a single therapy to treat many mutations causing blindness by transferring lost photoreceptor functions to other retinal cells. These new techniques could help gene therapy reach more diseases.
Targacept- neuronal nicotinic receptors
Targacept is a biopharmaceutical company located in Winston-Salem, NC that was founded in 1997 and has 117 employees. They research disorders of the central nervous system by targeting the nicotinic subtype of acetylcholine neurons in the brain. During their first three years, they were a subsidiary of RJ Reynolds and published many articles on the molecular effects of nicotine and the potential of the neuronal nicotinic receptor as a therapeutic target. They currently have five drug candidates in development for conditions like depression, ADHD, and Alzheimer's, and are conducting a Phase II clinical trial of TC-5619 as an adjunct treatment for cognitive dysfunction in schizophrenia.
Protein ZEB1 and resistance to radiation therapy, and antibodies to damage lungs
The document discusses two studies related to protein interactions that influence disease resistance and treatment outcomes. One study found that the ZEB1 protein can promote breast tumor resistance to radiation therapy by activating DNA damage response pathways. The other found that a type of antibody, IgG2, can allow lung-damaging bacteria to evade destruction by preventing complement protein formation on the bacteria's surface. Both studies provide insight into new treatment resistance mechanisms and potential targets for developing improved therapies.
Sara's rise proposal #2
This document discusses using induced pluripotent stem cells (iPSCs) derived from a patient's own skin cells to generate dopamine-producing neurons for treating Parkinson's disease. Parkinson's involves the death of dopamine neurons in the brain. Previous research using embryonic stem cells in rodents led to tumor formation. The proposed methodology would involve taking skin cells from rodents, generating iPSCs, differentiating them into dopamine neurons, and surgically implanting them into the rodents' brains. This approach could reduce immunorejection risks and provide a new treatment for Parkinson's by replacing lost dopamine neurons. Future studies would assess the safety and effectiveness of this iPSC-based therapy.
molecular biology folding
This document discusses recent discoveries about how certain genes and proteins play roles in various biological processes and diseases. It summarizes two research papers that found: 1) Variants of a gene called AARS can impact brain cells, immune cells, p53 signaling, apoptosis, tumorigenesis and angiogenesis. 2) Poly-peptides encoded by the C9ORF72 gene bind to nucleoli, impair RNA biogenesis, and kill cells, providing insights into neurodegenerative diseases like Alzheimer's and ALS. The student believes these findings could lead to new treatment approaches targeting the underlying causes rather than just symptoms of diseases.
BDSRA 2015 CLN6 Mole
This document summarizes the results of a study testing a gene therapy approach to treat vision loss in a mouse model of Batten disease. The study found that:
1) Photoreceptor function and cells are lost early in Cln6 mice, making it a good model.
2) Treating only photoreceptors with an AAV virus carrying Cln6 did not prevent retinal degeneration, as Cln6 is more highly expressed in inner retinal cells.
3) A new AAV virus was obtained that can target inner retinal cells like bipolar cells, which normally express high Cln6 levels. Future work will treat Cln6 mice with this new virus alone and combined with the original
Biomedical Autism Treatment - Yes, it Could Help Your Autistic Child!
DOAST (Doctrine Oriented Art of Symbiotic Treatment), an integrated therapy centre for autism, Chennai is one of the best autism treatment centre in India, provides best solution for autistic children by improving their behaviour and cognition through integrated therapy. For more details,visit: http://www.autism-ent-specialist-chennai.com
Eko med 23-ispr.
Dr. Adriana Bora is submitting a research proposal to the Society for Neuroscience for the Peter and Patricia Gruber International Research Award, supported by the Gruber Foundation. Her proposal focuses on developing novel clinical assays using functional peptidomics/metabolomics to better understand and monitor the different stages of HIV-associated neurological disorders in patients, even those receiving antiretroviral therapy. She has previously identified important glycoproteins and biomakers in cerebral spinal fluid that are involved in various pathways impacted by HIV in the brain. Her future research aims to identify alternative pathways and routes used by HIV to alter brain metabolism and cause impairment, which could lead to more personalized treatment approaches for HAND patients.
Eko Med 22 budimirovic
1) The document discusses the research of Dr. Adriana Bora into biomarkers for neurological disorders like HIV-associated neurological disorders (HAND) and autism spectrum disorder (ASD) using "omics" tools.
2) Her current research at Johns Hopkins has led to the discovery of novel protein biomarkers for early diagnosis of HAND. She is investigating molecular pathways affected by HIV in the brain using bioinformatics.
3) Working with Dr. Dejan Budimirovic, she is exploring the role of neuropeptides in ASD metabolism and developing assays to detect signature brain peptides in cerebral spinal fluid as potential ASD biomarkers.
4IJMPD-21-pdf-Parkinson’s Disease: A review
Parkinson’s Disease is the second most common progressive neurodegenerative disorder affecting older American adults and is predicted to increase in prevalence as the United States population ages. Resulting from a pathophysiologic loss or degeneration of dopaminergic neurons in the substantia nigra of the midbrain and the development of neuronal Lewy Bodies, idiopathic Parkinson’s Disease is associated with risk factors including aging, family history, pesticide exposure and environmental chemicals (e.g., synthetic heroin use). Its ultimate cause(s) is (are) unknown. Characterized by both motor and non-motor symptoms, PD patients classically display rest tremor, rigidity, bradykinesia, and stooping posture. PD can also be associated with neurobehavioral disorders (depression, anxiety), cognitive impairment (dementia), and autonomic dysfunction (e.g., orthostasis and hyperhidrosis). Recent decades have witnessed a proliferation of medical pharmacologic therapies and innovative surgical interventions like deep brain stimulation (DBS). However, definitive disease-modifying therapy is still lacking. Experimental therapies are being developed and tested with limited results. Knowledge of strategies to promote optimal quality of life for PD patients is of paramount importance for caregivers, health providers and patients themselves.
Jnnt 3-016-1
This document discusses a Turing machine theory approach to developing a new therapeutic strategy for some spinal cord and brain conditions using depurative, toxicological, and pharmacological methods. It reviews literature on neurodegenerative diseases and toxic accumulation in the brain and spinal cord. The document suggests developing a conceptual map to translate needs into a practical hypothesis. It examines questions about the roles of the immune system and brain waste removal systems in neurodegeneration and toxic accumulation in different brain regions.
Translational Neuroscience Approach in psychiatry..pptx
Translational neuroscience aims to bridge the gap between fundamental scientific research and clinical applications to treat neurological disorders. It focuses on applying discoveries from preclinical research, like animal and cell models, to develop new therapies. Translational neuroscience research occurs across both wet labs, which use experimental techniques, and dry labs, which analyze data through computational methods. The goal is to more quickly translate basic scientific findings into clinical applications that can improve patient outcomes. Identifying biomarkers that indicate disease mechanisms or predict treatment responses is an important part of translational research efforts.
Biomarcadores en epilepsia
This document discusses biomarkers for epileptogenesis and the challenges in developing clinically useful biomarkers to predict epilepsy risk, progression, and treatment response. It notes that while many potential biomarkers have been identified in preclinical studies, none have translated to clinical use. Some key challenges include the long timescales between injury and seizures, heterogeneity of epilepsy types and patients, and a focus on retrospective studies in refractory epilepsy patients rather than prospective validation. The document argues that combinatorial biomarkers analyzing multiple mechanisms may be more promising than single biomarkers, and that biomarkers should be validated as direct measures of patient outcomes rather than relying solely on seizure occurrence.
CIACI_2015
Long-term cognitive impairment after critical illness (CIACI) is frequently reported in up to 66% of patients three months after intensive care hospitalization. The condition has overlapping neurological changes with stroke, traumatic brain injury, and neurodegenerative disorders. Risk factors for CIACI include depression, biomarkers for Alzheimer's disease, delirium duration during hospitalization, and exposure to certain drugs. Current strategies to prevent or treat CIACI focus on reducing delirium and agitation, as well as physical and cognitive rehabilitation. Neurotrophic factors may play a role in neurogenesis, blood-brain barrier integrity, and neuronal repair, suggesting they could be a potential target for novel CIACI treatments.
Pacitane nanoparticles drug release for brain disorder
This document summarizes research on using nanoparticles to deliver drugs to the brain and treat brain disorders. It discusses how nanoparticles carrying drugs can be administered orally and pass through the gastrointestinal tract and bloodstream to reach the brain. Specifically, it describes an experiment where pacitane nanoparticles were prepared and tested as a potential delivery system for treating brain disorders like Parkinson's disease and schizophrenia. The nanoparticles were characterized and tested for drug release in vitro. The results showed 80% of the drug was released within 24 hours. The conclusion is that nanoparticle drug delivery could provide an effective therapy for brain disorders.
Kumarshivam (2)
This document discusses recent advances in the diagnosis and treatment of schizophrenia and Alzheimer's/dementia. It provides definitions of schizophrenia and Alzheimer's disease, describing them as neurological disorders. The causes, diagnoses, and treatments of each are discussed, along with limitations in current treatments and prospects for future treatment improvements. Biochemical and molecular analyses of both conditions are also reviewed.
Statistical, Energy Values And Peak Analysis (SEP) Approach For Detection of ...
ABSTRACT: In this paper, a technique of statistical, Energy values and peak analysis (SEP) approach is used for detection of neurodegenerative diseases from the signal of force sensitive resistors. In this work within the time series Left Stride Interval, Right Stride Interval, Left Swing Interval, Right Swing Interval, Left Stance Interval, Right Stance Interval and Double support interval are obtained and apply the SEP method. In statistical analysis, energy, standard deviation, mean, variance, co-variance are calculated. Two approximations and two details of energy values are extracted from wavelet decomposition. Average peak interval and peak histogram are calculated using peak analysis. Support Vector Machine (SVM) and Random Forest are used as a classifier. Data sets which include a healthy control (HC), various types of Neuro degenerative Diseases: Parkinson’s Disease (PD), Huntington Disease (HD), Amyotrophic Lateral Sclerosis. For disease diagnostic Force Sensitive resistor signals are used for evaluation. The results show that the proposed technique can successfully detect the NDD pathologies. For NDD detection, the accuracy, the Sensitivity, the Specificity values are 97%, 97% and 97% using Random forest Classifier.
Jnnd luisetto m nili ahmadabadi b mashori et al brain and immune system kuru...
Jnnd luisetto m nili ahmadabadi b mashori et al brain and immune system kuru...M. Luisetto Pharm.D.Spec. Pharmacology
The document discusses the relationship between the immune system and the brain in the context of KURU disease. KURU is transmitted orally through cannibalistic rituals, and there is a slow progression from ingestion to symptoms. The innate immune system plays a role in transmitting prions from the gastrointestinal system to the brain. Studying KURU can provide insights into immune-brain interactions and the progression of prion diseases that could help develop new treatment strategies for other neurodegenerative diseases also involving innate immunity.Annovis Bio (ANVS) Presentation - April 28, 2020
Annovis Bio is a clinical-stage, drug platform company addressing neurodegeneration, such as Alzheimer’s disease (AD), Parkinson’s disease (PD) and Alzheimer’s in Down Syndrome (AD-DS). Annovis is believed to be the only company developing a drug for AD, PD and AD-DS that inhibits more than one neurotoxic protein and improves the information highway of the nerve cell, known as axonal transport. When this information flow is impaired, the nerve cell gets sick and dies. The company expects its treatment to improve memory loss and dementia associated with AD and AD-DS, as well as body and brain function in PD. Annovis has an ongoing Phase 2a study in AD patients and plans to commence a second Phase 2a study in PD patients.
Gene therapy for Parkinson’s disease
Gene therapy aims to treat Parkinson's disease by inserting genes into cells to correct deficiencies. It has advantages over traditional treatments by potentially targeting the underlying causes and slowing disease progression. Two main approaches are ex vivo gene therapy, where cells are modified outside the body, and in vivo gene therapy through direct brain injection. Viral vectors are commonly used to deliver genes but carry risks. Ongoing research is exploring using gene therapy to restore dopamine synthesis, modulate basal ganglia activity, or provide neuroprotection for Parkinson's.
MOJPB-03-00085
1) The document discusses emerging proteomics and genomics biomarkers for diagnosing Alzheimer's disease (AD), noting that current biomarkers like cerebrospinal fluid levels have limited accuracy.
2) It suggests that multi-biomarker approaches combining proteins associated with AD and vascular diseases may improve diagnostic accuracy.
3) MicroRNAs found in biofluids like cerebrospinal fluid and blood show potential as AD biomarkers, and combining multiple biomarkers into diagnostic profiles could help predict which individuals will progress from mild cognitive impairment to AD dementia.
Submission Ide 88c19114-7d71-4703-b679-22f6c2ee580479 SI.docx
Submission Ide: 88c19114-7d71-4703-b679-22f6c2ee5804
79% SIMILARITY SCORE 4 CITATION ITEMS 66 GRAMMAR ISSUES 0 FEEDBACK COMMENT
Internet Source 79%
Institution 0%
Muhammad Aftkhar
Parkinsonism- Pharmaceutical Treatment Plan.docx
Summary
1140 Words
1
Running Header: PARKINSON'S DISEASE
2
PARKINSON'S DISEASE
Parkinson’s disease
Parkinson's disease is a neuro de-generative disease that occurs and depletes the neurons
present in substansia nigra. These neurons are involved in the transmission of nerve impulses
Web Content: https://mynursingexperts.com/checking-and-assignment-corection/…
Spelling mistake: neuro euro
Spelling mista...: de-generative degenerative
PARKINSON'S DISEASE
MUHAMMAD AFTKHAR
NUR 635 (GCU)
Mar 4th, 2020
https://www.researchgate.net/profile/Charles_Davie/publication/5454757_A_review_of_Parkinson's_disease/links/5866522a08ae8fce490ee2e6/A-review-of-Parkinsons-disease.pdf
https://www.researchgate.net/profile/Charles_Davie/publication/5454757_A_review_of_Parkinson's_disease/links/5866522a08ae8fce490ee2e6/A-review-of-Parkinsons-disease.pdf
https://www.sciencedirect.com/science/article/abs/pii/S1474442218302394
https://www.sciencedirect.com/science/article/abs/pii/S1043661818321078
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4140171/
from corpus collosum to the susbtansia nigra part of the mid brain. These are the character
playing neurons in managing voluntary motor movements in the body. It mostly occurs in elderly
patients describe by involuntary movements and multi-dimensional brain functioning. The part
of this disease may occur due to the effective and excessive use of medications indulging in bi
polar or Alzheimer's disease (Davie, 2008). The decline of dopamine in par compacta
deteriorates the normal functioning of the brain in controlling motor activities.
Prescription medication
The prescribed medications used for Parkinson’s disease includes the use of Levodopa
directly with replenishes the pool for dopamine neurotransmitter. This drug can’t be given in a
single dose rather without carbidopa (LODOSYN) the levodopa will break down into dopamine
and then to epinephrine in the body’s periphery. This will create severe symptomatic side effects
like an increase in heart rate and sympathetic system dominancy. Dopa-decarboxylase enzyme
breaks down the levodopa in the periphery so along with levodopa carbidopa is given. This
inhibits the dopa-decarboxylase enzyme and allows levodopa to travel into the blood brain
barrier easily.
For the calculations of drug regimen there must be precautionary measures for kidney
and liver sensitive enzyme dependent patients. LFT and RFT’s for sensitive patients are done to
ensure the correct for dose adjustments not lying in range affecting kidneys and liver function.
Below are some of the medications for Parkinson’s d.
Submission Ide 88c19114-7d71-4703-b679-22f6c2ee580479 SI.docx
Submission Ide: 88c19114-7d71-4703-b679-22f6c2ee5804
79% SIMILARITY SCORE 4 CITATION ITEMS 66 GRAMMAR ISSUES 0 FEEDBACK COMMENT
Internet Source 79%
Institution 0%
Muhammad Aftkhar
Parkinsonism- Pharmaceutical Treatment Plan.docx
Summary
1140 Words
1
Running Header: PARKINSON'S DISEASE
2
PARKINSON'S DISEASE
Parkinson’s disease
Parkinson's disease is a neuro de-generative disease that occurs and depletes the neurons
present in substansia nigra. These neurons are involved in the transmission of nerve impulses
Web Content: https://mynursingexperts.com/checking-and-assignment-corection/…
Spelling mistake: neuro euro
Spelling mista...: de-generative degenerative
PARKINSON'S DISEASE
MUHAMMAD AFTKHAR
NUR 635 (GCU)
Mar 4th, 2020
https://www.researchgate.net/profile/Charles_Davie/publication/5454757_A_review_of_Parkinson's_disease/links/5866522a08ae8fce490ee2e6/A-review-of-Parkinsons-disease.pdf
https://www.researchgate.net/profile/Charles_Davie/publication/5454757_A_review_of_Parkinson's_disease/links/5866522a08ae8fce490ee2e6/A-review-of-Parkinsons-disease.pdf
https://www.sciencedirect.com/science/article/abs/pii/S1474442218302394
https://www.sciencedirect.com/science/article/abs/pii/S1043661818321078
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4140171/
from corpus collosum to the susbtansia nigra part of the mid brain. These are the character
playing neurons in managing voluntary motor movements in the body. It mostly occurs in elderly
patients describe by involuntary movements and multi-dimensional brain functioning. The part
of this disease may occur due to the effective and excessive use of medications indulging in bi
polar or Alzheimer's disease (Davie, 2008). The decline of dopamine in par compacta
deteriorates the normal functioning of the brain in controlling motor activities.
Prescription medication
The prescribed medications used for Parkinson’s disease includes the use of Levodopa
directly with replenishes the pool for dopamine neurotransmitter. This drug can’t be given in a
single dose rather without carbidopa (LODOSYN) the levodopa will break down into dopamine
and then to epinephrine in the body’s periphery. This will create severe symptomatic side effects
like an increase in heart rate and sympathetic system dominancy. Dopa-decarboxylase enzyme
breaks down the levodopa in the periphery so along with levodopa carbidopa is given. This
inhibits the dopa-decarboxylase enzyme and allows levodopa to travel into the blood brain
barrier easily.
For the calculations of drug regimen there must be precautionary measures for kidney
and liver sensitive enzyme dependent patients. LFT and RFT’s for sensitive patients are done to
ensure the correct for dose adjustments not lying in range affecting kidneys and liver function.
Below are some of the medications for Parkinson’s d.
Detection of Parkinson’s disease using python.pptx
this is a ppt describing novel method for early detection of parkinson's disease which prevents undergoing tedious medical procedure
Autoimmune encephalitis 144
This document summarizes autoimmune encephalitis and its implications for psychiatry. It discusses various types of autoimmune encephalitis including limbic encephalitis, anti-NMDA receptor antibody encephalitis, and PANDAS. It notes that autoimmune encephalitis can present with primarily psychiatric symptoms and be misdiagnosed as psychiatric conditions. The document recommends investigations like antibody testing and CSF analysis and treatments like immunotherapy for suspected cases. It also reviews literature linking immune abnormalities and inflammation to conditions like schizophrenia and depression.
BME 620 Feasibility Analysis by Sz-Wei Wu_2
This document summarizes a feasibility analysis for a proposed method to control diseases by manipulating the relationship between the immune and nervous systems using bioelectronic techniques. It first provides background on the costs of diseases related to immune response and the potential market opportunity. It then reviews the physiology of interactions between the central/peripheral nervous, endocrine and immune systems, focusing on the role of the vagus nerve in immunomodulation. Specifically, it discusses how vagus nerve stimulation has anti-inflammatory effects and been shown to ameliorate systemic inflammation in previous research. The document proposes developing a device to help gain more objective results from neuromodulation techniques for immune applications.
SAR BY NMR (Structure Activity Relationship by Using NMR)
SAR by NMR is the Nuclear Magnetic Resonance (NMR) based method in which small organic molecules that bind to the proximal site are identified, optimized and finally linked together to produce high-affinity ligands.
It is called “SAR by NMR” because the structure-activity relationship (SAR) is obtained by the Nuclear Magnetic Resonance (NMR).
It is based on the fragments approaches to drug design.
With this technique, compounds with nanomolar affinity for a target protein can be rapidly discovered by tethering two ligands with micromolar affinities.
The method reduces the chemical synthesis and the time required for the discovery of high-affinity ligands and is particularly useful in target-directed drugs research.
Galantamine Anti-Colitic Effect
The document presents research investigating the anti-colitic effect of galantamine. The study hypothesized that galantamine modulates inflammatory pathways like Jak/STAT3, NF-κB/HMGB1/RAGE, and p-AKT/Bcl-2 through the alpha-7 nicotinic acetylcholine receptor. Experiments showed that galantamine reduced ulcer area and inflammatory markers in a colitis model, and this effect was blocked when administered with an alpha-7 receptor antagonist. The study concludes that galantamine exerts anti-inflammatory effects by positively modulating the alpha-7 receptor and stimulating the cholinergic anti-inflammatory pathway.
More Related Content
Similar to Immunotherapy for Parkinson's Disease
Biomedical Autism Treatment - Yes, it Could Help Your Autistic Child!
DOAST (Doctrine Oriented Art of Symbiotic Treatment), an integrated therapy centre for autism, Chennai is one of the best autism treatment centre in India, provides best solution for autistic children by improving their behaviour and cognition through integrated therapy. For more details,visit: http://www.autism-ent-specialist-chennai.com
Eko med 23-ispr.
Dr. Adriana Bora is submitting a research proposal to the Society for Neuroscience for the Peter and Patricia Gruber International Research Award, supported by the Gruber Foundation. Her proposal focuses on developing novel clinical assays using functional peptidomics/metabolomics to better understand and monitor the different stages of HIV-associated neurological disorders in patients, even those receiving antiretroviral therapy. She has previously identified important glycoproteins and biomakers in cerebral spinal fluid that are involved in various pathways impacted by HIV in the brain. Her future research aims to identify alternative pathways and routes used by HIV to alter brain metabolism and cause impairment, which could lead to more personalized treatment approaches for HAND patients.
Eko Med 22 budimirovic
1) The document discusses the research of Dr. Adriana Bora into biomarkers for neurological disorders like HIV-associated neurological disorders (HAND) and autism spectrum disorder (ASD) using "omics" tools.
2) Her current research at Johns Hopkins has led to the discovery of novel protein biomarkers for early diagnosis of HAND. She is investigating molecular pathways affected by HIV in the brain using bioinformatics.
3) Working with Dr. Dejan Budimirovic, she is exploring the role of neuropeptides in ASD metabolism and developing assays to detect signature brain peptides in cerebral spinal fluid as potential ASD biomarkers.
4IJMPD-21-pdf-Parkinson’s Disease: A review
Parkinson’s Disease is the second most common progressive neurodegenerative disorder affecting older American adults and is predicted to increase in prevalence as the United States population ages. Resulting from a pathophysiologic loss or degeneration of dopaminergic neurons in the substantia nigra of the midbrain and the development of neuronal Lewy Bodies, idiopathic Parkinson’s Disease is associated with risk factors including aging, family history, pesticide exposure and environmental chemicals (e.g., synthetic heroin use). Its ultimate cause(s) is (are) unknown. Characterized by both motor and non-motor symptoms, PD patients classically display rest tremor, rigidity, bradykinesia, and stooping posture. PD can also be associated with neurobehavioral disorders (depression, anxiety), cognitive impairment (dementia), and autonomic dysfunction (e.g., orthostasis and hyperhidrosis). Recent decades have witnessed a proliferation of medical pharmacologic therapies and innovative surgical interventions like deep brain stimulation (DBS). However, definitive disease-modifying therapy is still lacking. Experimental therapies are being developed and tested with limited results. Knowledge of strategies to promote optimal quality of life for PD patients is of paramount importance for caregivers, health providers and patients themselves.
Jnnt 3-016-1
This document discusses a Turing machine theory approach to developing a new therapeutic strategy for some spinal cord and brain conditions using depurative, toxicological, and pharmacological methods. It reviews literature on neurodegenerative diseases and toxic accumulation in the brain and spinal cord. The document suggests developing a conceptual map to translate needs into a practical hypothesis. It examines questions about the roles of the immune system and brain waste removal systems in neurodegeneration and toxic accumulation in different brain regions.
Translational Neuroscience Approach in psychiatry..pptx
Translational neuroscience aims to bridge the gap between fundamental scientific research and clinical applications to treat neurological disorders. It focuses on applying discoveries from preclinical research, like animal and cell models, to develop new therapies. Translational neuroscience research occurs across both wet labs, which use experimental techniques, and dry labs, which analyze data through computational methods. The goal is to more quickly translate basic scientific findings into clinical applications that can improve patient outcomes. Identifying biomarkers that indicate disease mechanisms or predict treatment responses is an important part of translational research efforts.
Biomarcadores en epilepsia
This document discusses biomarkers for epileptogenesis and the challenges in developing clinically useful biomarkers to predict epilepsy risk, progression, and treatment response. It notes that while many potential biomarkers have been identified in preclinical studies, none have translated to clinical use. Some key challenges include the long timescales between injury and seizures, heterogeneity of epilepsy types and patients, and a focus on retrospective studies in refractory epilepsy patients rather than prospective validation. The document argues that combinatorial biomarkers analyzing multiple mechanisms may be more promising than single biomarkers, and that biomarkers should be validated as direct measures of patient outcomes rather than relying solely on seizure occurrence.
CIACI_2015
Long-term cognitive impairment after critical illness (CIACI) is frequently reported in up to 66% of patients three months after intensive care hospitalization. The condition has overlapping neurological changes with stroke, traumatic brain injury, and neurodegenerative disorders. Risk factors for CIACI include depression, biomarkers for Alzheimer's disease, delirium duration during hospitalization, and exposure to certain drugs. Current strategies to prevent or treat CIACI focus on reducing delirium and agitation, as well as physical and cognitive rehabilitation. Neurotrophic factors may play a role in neurogenesis, blood-brain barrier integrity, and neuronal repair, suggesting they could be a potential target for novel CIACI treatments.
Pacitane nanoparticles drug release for brain disorder
This document summarizes research on using nanoparticles to deliver drugs to the brain and treat brain disorders. It discusses how nanoparticles carrying drugs can be administered orally and pass through the gastrointestinal tract and bloodstream to reach the brain. Specifically, it describes an experiment where pacitane nanoparticles were prepared and tested as a potential delivery system for treating brain disorders like Parkinson's disease and schizophrenia. The nanoparticles were characterized and tested for drug release in vitro. The results showed 80% of the drug was released within 24 hours. The conclusion is that nanoparticle drug delivery could provide an effective therapy for brain disorders.
Kumarshivam (2)
This document discusses recent advances in the diagnosis and treatment of schizophrenia and Alzheimer's/dementia. It provides definitions of schizophrenia and Alzheimer's disease, describing them as neurological disorders. The causes, diagnoses, and treatments of each are discussed, along with limitations in current treatments and prospects for future treatment improvements. Biochemical and molecular analyses of both conditions are also reviewed.
Statistical, Energy Values And Peak Analysis (SEP) Approach For Detection of ...
ABSTRACT: In this paper, a technique of statistical, Energy values and peak analysis (SEP) approach is used for detection of neurodegenerative diseases from the signal of force sensitive resistors. In this work within the time series Left Stride Interval, Right Stride Interval, Left Swing Interval, Right Swing Interval, Left Stance Interval, Right Stance Interval and Double support interval are obtained and apply the SEP method. In statistical analysis, energy, standard deviation, mean, variance, co-variance are calculated. Two approximations and two details of energy values are extracted from wavelet decomposition. Average peak interval and peak histogram are calculated using peak analysis. Support Vector Machine (SVM) and Random Forest are used as a classifier. Data sets which include a healthy control (HC), various types of Neuro degenerative Diseases: Parkinson’s Disease (PD), Huntington Disease (HD), Amyotrophic Lateral Sclerosis. For disease diagnostic Force Sensitive resistor signals are used for evaluation. The results show that the proposed technique can successfully detect the NDD pathologies. For NDD detection, the accuracy, the Sensitivity, the Specificity values are 97%, 97% and 97% using Random forest Classifier.
Jnnd luisetto m nili ahmadabadi b mashori et al brain and immune system kuru...
Jnnd luisetto m nili ahmadabadi b mashori et al brain and immune system kuru...M. Luisetto Pharm.D.Spec. Pharmacology
The document discusses the relationship between the immune system and the brain in the context of KURU disease. KURU is transmitted orally through cannibalistic rituals, and there is a slow progression from ingestion to symptoms. The innate immune system plays a role in transmitting prions from the gastrointestinal system to the brain. Studying KURU can provide insights into immune-brain interactions and the progression of prion diseases that could help develop new treatment strategies for other neurodegenerative diseases also involving innate immunity.Annovis Bio (ANVS) Presentation - April 28, 2020
Annovis Bio is a clinical-stage, drug platform company addressing neurodegeneration, such as Alzheimer’s disease (AD), Parkinson’s disease (PD) and Alzheimer’s in Down Syndrome (AD-DS). Annovis is believed to be the only company developing a drug for AD, PD and AD-DS that inhibits more than one neurotoxic protein and improves the information highway of the nerve cell, known as axonal transport. When this information flow is impaired, the nerve cell gets sick and dies. The company expects its treatment to improve memory loss and dementia associated with AD and AD-DS, as well as body and brain function in PD. Annovis has an ongoing Phase 2a study in AD patients and plans to commence a second Phase 2a study in PD patients.
Gene therapy for Parkinson’s disease
Gene therapy aims to treat Parkinson's disease by inserting genes into cells to correct deficiencies. It has advantages over traditional treatments by potentially targeting the underlying causes and slowing disease progression. Two main approaches are ex vivo gene therapy, where cells are modified outside the body, and in vivo gene therapy through direct brain injection. Viral vectors are commonly used to deliver genes but carry risks. Ongoing research is exploring using gene therapy to restore dopamine synthesis, modulate basal ganglia activity, or provide neuroprotection for Parkinson's.
MOJPB-03-00085
1) The document discusses emerging proteomics and genomics biomarkers for diagnosing Alzheimer's disease (AD), noting that current biomarkers like cerebrospinal fluid levels have limited accuracy.
2) It suggests that multi-biomarker approaches combining proteins associated with AD and vascular diseases may improve diagnostic accuracy.
3) MicroRNAs found in biofluids like cerebrospinal fluid and blood show potential as AD biomarkers, and combining multiple biomarkers into diagnostic profiles could help predict which individuals will progress from mild cognitive impairment to AD dementia.
Submission Ide 88c19114-7d71-4703-b679-22f6c2ee580479 SI.docx
Submission Ide: 88c19114-7d71-4703-b679-22f6c2ee5804
79% SIMILARITY SCORE 4 CITATION ITEMS 66 GRAMMAR ISSUES 0 FEEDBACK COMMENT
Internet Source 79%
Institution 0%
Muhammad Aftkhar
Parkinsonism- Pharmaceutical Treatment Plan.docx
Summary
1140 Words
1
Running Header: PARKINSON'S DISEASE
2
PARKINSON'S DISEASE
Parkinson’s disease
Parkinson's disease is a neuro de-generative disease that occurs and depletes the neurons
present in substansia nigra. These neurons are involved in the transmission of nerve impulses
Web Content: https://mynursingexperts.com/checking-and-assignment-corection/…
Spelling mistake: neuro euro
Spelling mista...: de-generative degenerative
PARKINSON'S DISEASE
MUHAMMAD AFTKHAR
NUR 635 (GCU)
Mar 4th, 2020
https://www.researchgate.net/profile/Charles_Davie/publication/5454757_A_review_of_Parkinson's_disease/links/5866522a08ae8fce490ee2e6/A-review-of-Parkinsons-disease.pdf
https://www.researchgate.net/profile/Charles_Davie/publication/5454757_A_review_of_Parkinson's_disease/links/5866522a08ae8fce490ee2e6/A-review-of-Parkinsons-disease.pdf
https://www.sciencedirect.com/science/article/abs/pii/S1474442218302394
https://www.sciencedirect.com/science/article/abs/pii/S1043661818321078
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4140171/
from corpus collosum to the susbtansia nigra part of the mid brain. These are the character
playing neurons in managing voluntary motor movements in the body. It mostly occurs in elderly
patients describe by involuntary movements and multi-dimensional brain functioning. The part
of this disease may occur due to the effective and excessive use of medications indulging in bi
polar or Alzheimer's disease (Davie, 2008). The decline of dopamine in par compacta
deteriorates the normal functioning of the brain in controlling motor activities.
Prescription medication
The prescribed medications used for Parkinson’s disease includes the use of Levodopa
directly with replenishes the pool for dopamine neurotransmitter. This drug can’t be given in a
single dose rather without carbidopa (LODOSYN) the levodopa will break down into dopamine
and then to epinephrine in the body’s periphery. This will create severe symptomatic side effects
like an increase in heart rate and sympathetic system dominancy. Dopa-decarboxylase enzyme
breaks down the levodopa in the periphery so along with levodopa carbidopa is given. This
inhibits the dopa-decarboxylase enzyme and allows levodopa to travel into the blood brain
barrier easily.
For the calculations of drug regimen there must be precautionary measures for kidney
and liver sensitive enzyme dependent patients. LFT and RFT’s for sensitive patients are done to
ensure the correct for dose adjustments not lying in range affecting kidneys and liver function.
Below are some of the medications for Parkinson’s d.
Submission Ide 88c19114-7d71-4703-b679-22f6c2ee580479 SI.docx
Submission Ide: 88c19114-7d71-4703-b679-22f6c2ee5804
79% SIMILARITY SCORE 4 CITATION ITEMS 66 GRAMMAR ISSUES 0 FEEDBACK COMMENT
Internet Source 79%
Institution 0%
Muhammad Aftkhar
Parkinsonism- Pharmaceutical Treatment Plan.docx
Summary
1140 Words
1
Running Header: PARKINSON'S DISEASE
2
PARKINSON'S DISEASE
Parkinson’s disease
Parkinson's disease is a neuro de-generative disease that occurs and depletes the neurons
present in substansia nigra. These neurons are involved in the transmission of nerve impulses
Web Content: https://mynursingexperts.com/checking-and-assignment-corection/…
Spelling mistake: neuro euro
Spelling mista...: de-generative degenerative
PARKINSON'S DISEASE
MUHAMMAD AFTKHAR
NUR 635 (GCU)
Mar 4th, 2020
https://www.researchgate.net/profile/Charles_Davie/publication/5454757_A_review_of_Parkinson's_disease/links/5866522a08ae8fce490ee2e6/A-review-of-Parkinsons-disease.pdf
https://www.researchgate.net/profile/Charles_Davie/publication/5454757_A_review_of_Parkinson's_disease/links/5866522a08ae8fce490ee2e6/A-review-of-Parkinsons-disease.pdf
https://www.sciencedirect.com/science/article/abs/pii/S1474442218302394
https://www.sciencedirect.com/science/article/abs/pii/S1043661818321078
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4140171/
from corpus collosum to the susbtansia nigra part of the mid brain. These are the character
playing neurons in managing voluntary motor movements in the body. It mostly occurs in elderly
patients describe by involuntary movements and multi-dimensional brain functioning. The part
of this disease may occur due to the effective and excessive use of medications indulging in bi
polar or Alzheimer's disease (Davie, 2008). The decline of dopamine in par compacta
deteriorates the normal functioning of the brain in controlling motor activities.
Prescription medication
The prescribed medications used for Parkinson’s disease includes the use of Levodopa
directly with replenishes the pool for dopamine neurotransmitter. This drug can’t be given in a
single dose rather without carbidopa (LODOSYN) the levodopa will break down into dopamine
and then to epinephrine in the body’s periphery. This will create severe symptomatic side effects
like an increase in heart rate and sympathetic system dominancy. Dopa-decarboxylase enzyme
breaks down the levodopa in the periphery so along with levodopa carbidopa is given. This
inhibits the dopa-decarboxylase enzyme and allows levodopa to travel into the blood brain
barrier easily.
For the calculations of drug regimen there must be precautionary measures for kidney
and liver sensitive enzyme dependent patients. LFT and RFT’s for sensitive patients are done to
ensure the correct for dose adjustments not lying in range affecting kidneys and liver function.
Below are some of the medications for Parkinson’s d.
Detection of Parkinson’s disease using python.pptx
this is a ppt describing novel method for early detection of parkinson's disease which prevents undergoing tedious medical procedure
Autoimmune encephalitis 144
This document summarizes autoimmune encephalitis and its implications for psychiatry. It discusses various types of autoimmune encephalitis including limbic encephalitis, anti-NMDA receptor antibody encephalitis, and PANDAS. It notes that autoimmune encephalitis can present with primarily psychiatric symptoms and be misdiagnosed as psychiatric conditions. The document recommends investigations like antibody testing and CSF analysis and treatments like immunotherapy for suspected cases. It also reviews literature linking immune abnormalities and inflammation to conditions like schizophrenia and depression.
BME 620 Feasibility Analysis by Sz-Wei Wu_2
This document summarizes a feasibility analysis for a proposed method to control diseases by manipulating the relationship between the immune and nervous systems using bioelectronic techniques. It first provides background on the costs of diseases related to immune response and the potential market opportunity. It then reviews the physiology of interactions between the central/peripheral nervous, endocrine and immune systems, focusing on the role of the vagus nerve in immunomodulation. Specifically, it discusses how vagus nerve stimulation has anti-inflammatory effects and been shown to ameliorate systemic inflammation in previous research. The document proposes developing a device to help gain more objective results from neuromodulation techniques for immune applications.
Similar to Immunotherapy for Parkinson's Disease (20)
Biomedical Autism Treatment - Yes, it Could Help Your Autistic Child!
Biomedical Autism Treatment - Yes, it Could Help Your Autistic Child!
Translational Neuroscience Approach in psychiatry..pptx
Translational Neuroscience Approach in psychiatry..pptx
Pacitane nanoparticles drug release for brain disorder
Pacitane nanoparticles drug release for brain disorder
Statistical, Energy Values And Peak Analysis (SEP) Approach For Detection of ...
Statistical, Energy Values And Peak Analysis (SEP) Approach For Detection of ...
Jnnd luisetto m nili ahmadabadi b mashori et al brain and immune system kuru...
Jnnd luisetto m nili ahmadabadi b mashori et al brain and immune system kuru...
Submission Ide 88c19114-7d71-4703-b679-22f6c2ee580479 SI.docx
Submission Ide 88c19114-7d71-4703-b679-22f6c2ee580479 SI.docx
Submission Ide 88c19114-7d71-4703-b679-22f6c2ee580479 SI.docx
Submission Ide 88c19114-7d71-4703-b679-22f6c2ee580479 SI.docx
Detection of Parkinson’s disease using python.pptx
Detection of Parkinson’s disease using python.pptx
More from SAKEEL AHMED
SAR BY NMR (Structure Activity Relationship by Using NMR)
SAR by NMR is the Nuclear Magnetic Resonance (NMR) based method in which small organic molecules that bind to the proximal site are identified, optimized and finally linked together to produce high-affinity ligands.
It is called “SAR by NMR” because the structure-activity relationship (SAR) is obtained by the Nuclear Magnetic Resonance (NMR).
It is based on the fragments approaches to drug design.
With this technique, compounds with nanomolar affinity for a target protein can be rapidly discovered by tethering two ligands with micromolar affinities.
The method reduces the chemical synthesis and the time required for the discovery of high-affinity ligands and is particularly useful in target-directed drugs research.
Galantamine Anti-Colitic Effect
The document presents research investigating the anti-colitic effect of galantamine. The study hypothesized that galantamine modulates inflammatory pathways like Jak/STAT3, NF-κB/HMGB1/RAGE, and p-AKT/Bcl-2 through the alpha-7 nicotinic acetylcholine receptor. Experiments showed that galantamine reduced ulcer area and inflammatory markers in a colitis model, and this effect was blocked when administered with an alpha-7 receptor antagonist. The study concludes that galantamine exerts anti-inflammatory effects by positively modulating the alpha-7 receptor and stimulating the cholinergic anti-inflammatory pathway.
Docking Score Functions
This document discusses docking scoring functions, which are mathematical functions used to predict the binding affinity between molecules after docking. There are three main applications of scoring functions: determining the binding mode of a ligand on a protein, predicting absolute binding affinity, and identifying potential drug hits through virtual screening. The document outlines different classes of scoring functions, including force field-based, empirical, knowledge-based, consensus, and shape/chemical complementary scores. It provides examples of popular docking programs that utilize different scoring function approaches.
Phospholipase D (PLD)
Phospholipase D catalyzes the hydrolysis of the phosphodiester bond of glycerophospholipids to generate phosphatidic acid and a free headgroup.
Phospholipase D (PLD) activity was first discovered in carrot extracts as a phospholipid-specific phosphodiesterase activity that hydrolysed phosphatidylcholine to yield phosphatidic acid (PA) and choline.
It is mainly specific for Phosphatidylcholine then Phosphatidylethanolamine.
Discovery of Aliskiren (Renin Inhibitor)
Aliskiren (Tekturna) is the first orally active renin inhibitor approved for clinical use. It was approved by the US Food and Drug Administration and the European Medicines Agency in 2007 for the treatment of Primary hypertension.
It was developed by Ciba-Geigy (now Novartis).
Peptidomimetics
This document discusses peptidomimetics, which are small protein-like chains designed to mimic peptides while having no peptide bonds and a molecular weight under 700 Daltons. Peptidomimetics are derived from bioactive peptides and aim to improve stability, transport properties, and activity while reducing degradation. They are classified based on their modifications from the original peptide. Common modification methods include cyclization, retro-inverso design, and restricting conformations through disulfide bonds or metal chelation. Peptidomimetics have therapeutic value as they can overcome issues like poor oral bioavailability that limit peptide drugs, as demonstrated for somatostatin analogs. Recent advances include using peptidomimetics to enhance peptide vaccines
Bee venom in Parkinson's Disease(PD)
Bee venom contain many components like bee venom phospholipase A2 and apamin etc
bee venom phospholipase A2 decrease the neuroinflammation in parkinson's disease helpful to treat PD.
Melanoma and Parkinson disease & Link between them.
Parkinson disease is the progressive neurodegenerative disorder in which mainly dopaminergic neuron in the substantia nigra pars compacta.
Melanoma is a type of skin cancer.
Centrosome and centrioles
This document discusses the centrosome and centrioles. It notes that the centrosome is the microtubule organizing center of eukaryotic cells, composed of two centrioles arranged perpendicular to each other surrounded by pericentriolar material. Each centriole contains nine triplet microtubules in a cartwheel structure and proteins like centrin, nexin, and tektin. The centrosome functions to form the mitotic spindle during cell division and organize microtubules. It duplicates during S phase and the mother and daughter centrioles migrate to opposite poles during mitosis to form the mitotic spindle between them.
Liraglutide in Diabetes
#Diabetes..
Liraglutide use in the Diabetes... Mechanism and novel approach for the delivery of liraglutide.....
Nerve growth factor (NGF) Signalling pathways.
Nerve growth factor is a small protein that promotes the growth, maintenance, and survival of neurons. It was discovered in 1956 by Rita Levi-Montalcini and Stanley Cohen. NGF signals through two pathways, the TrkA pathway which promotes cell survival and the p75 pathway which can promote both survival and apoptosis. NGF production decreases in conditions like Alzheimer's disease, impairing the ability to form new neural connections.
More from SAKEEL AHMED (11)
SAR BY NMR (Structure Activity Relationship by Using NMR)
SAR BY NMR (Structure Activity Relationship by Using NMR)
Melanoma and Parkinson disease & Link between them.
Melanoma and Parkinson disease & Link between them.
Recently uploaded
BBR 2024 Summer Sessions Interview Training
Qualitative research interview training by Professor Katrina Pritchard and Dr Helen Williams
Azure Interview Questions and Answers PDF By ScholarHat
Azure Interview Questions and Answers PDF By ScholarHat
ANATOMY AND BIOMECHANICS OF HIP JOINT.pdf
it describes the bony anatomy including the femoral head , acetabulum, labrum . also discusses the capsule , ligaments . muscle that act on the hip joint and the range of motion are outlined. factors affecting hip joint stability and weight transmission through the joint are summarized.
How to Make a Field Mandatory in Odoo 17
In Odoo, making a field required can be done through both Python code and XML views. When you set the required attribute to True in Python code, it makes the field required across all views where it's used. Conversely, when you set the required attribute in XML views, it makes the field required only in the context of that particular view.
ISO/IEC 27001, ISO/IEC 42001, and GDPR: Best Practices for Implementation and...
Denis is a dynamic and results-driven Chief Information Officer (CIO) with a distinguished career spanning information systems analysis and technical project management. With a proven track record of spearheading the design and delivery of cutting-edge Information Management solutions, he has consistently elevated business operations, streamlined reporting functions, and maximized process efficiency.
Certified as an ISO/IEC 27001: Information Security Management Systems (ISMS) Lead Implementer, Data Protection Officer, and Cyber Risks Analyst, Denis brings a heightened focus on data security, privacy, and cyber resilience to every endeavor.
His expertise extends across a diverse spectrum of reporting, database, and web development applications, underpinned by an exceptional grasp of data storage and virtualization technologies. His proficiency in application testing, database administration, and data cleansing ensures seamless execution of complex projects.
What sets Denis apart is his comprehensive understanding of Business and Systems Analysis technologies, honed through involvement in all phases of the Software Development Lifecycle (SDLC). From meticulous requirements gathering to precise analysis, innovative design, rigorous development, thorough testing, and successful implementation, he has consistently delivered exceptional results.
Throughout his career, he has taken on multifaceted roles, from leading technical project management teams to owning solutions that drive operational excellence. His conscientious and proactive approach is unwavering, whether he is working independently or collaboratively within a team. His ability to connect with colleagues on a personal level underscores his commitment to fostering a harmonious and productive workplace environment.
Date: May 29, 2024
Tags: Information Security, ISO/IEC 27001, ISO/IEC 42001, Artificial Intelligence, GDPR
-------------------------------------------------------------------------------
Find out more about ISO training and certification services
Training: ISO/IEC 27001 Information Security Management System - EN | PECB
ISO/IEC 42001 Artificial Intelligence Management System - EN | PECB
General Data Protection Regulation (GDPR) - Training Courses - EN | PECB
Webinars: https://pecb.com/webinars
Article: https://pecb.com/article
-------------------------------------------------------------------------------
For more information about PECB:
Website: https://pecb.com/
LinkedIn: https://www.linkedin.com/company/pecb/
Facebook: https://www.facebook.com/PECBInternational/
Slideshare: http://www.slideshare.net/PECBCERTIFICATION
Natural birth techniques - Mrs.Akanksha Trivedi Rama University
Natural birth techniques - Mrs.Akanksha Trivedi Rama UniversityAkanksha trivedi rama nursing college kanpur.
Natural birth techniques are various type such as/ water birth , alexender method, hypnosis, bradley method, lamaze method etcLAND USE LAND COVER AND NDVI OF MIRZAPUR DISTRICT, UP
This Dissertation explores the particular circumstances of Mirzapur, a region located in the
core of India. Mirzapur, with its varied terrains and abundant biodiversity, offers an optimal
environment for investigating the changes in vegetation cover dynamics. Our study utilizes
advanced technologies such as GIS (Geographic Information Systems) and Remote sensing to
analyze the transformations that have taken place over the course of a decade.
The complex relationship between human activities and the environment has been the focus
of extensive research and worry. As the global community grapples with swift urbanization,
population expansion, and economic progress, the effects on natural ecosystems are becoming
more evident. A crucial element of this impact is the alteration of vegetation cover, which plays a
significant role in maintaining the ecological equilibrium of our planet.Land serves as the foundation for all human activities and provides the necessary materials for
these activities. As the most crucial natural resource, its utilization by humans results in different
'Land uses,' which are determined by both human activities and the physical characteristics of the
land.
The utilization of land is impacted by human needs and environmental factors. In countries
like India, rapid population growth and the emphasis on extensive resource exploitation can lead
to significant land degradation, adversely affecting the region's land cover.
Therefore, human intervention has significantly influenced land use patterns over many
centuries, evolving its structure over time and space. In the present era, these changes have
accelerated due to factors such as agriculture and urbanization. Information regarding land use and
cover is essential for various planning and management tasks related to the Earth's surface,
providing crucial environmental data for scientific, resource management, policy purposes, and
diverse human activities.
Accurate understanding of land use and cover is imperative for the development planning
of any area. Consequently, a wide range of professionals, including earth system scientists, land
and water managers, and urban planners, are interested in obtaining data on land use and cover
changes, conversion trends, and other related patterns. The spatial dimensions of land use and
cover support policymakers and scientists in making well-informed decisions, as alterations in
these patterns indicate shifts in economic and social conditions. Monitoring such changes with the
help of Advanced technologies like Remote Sensing and Geographic Information Systems is
crucial for coordinated efforts across different administrative levels. Advanced technologies like
Remote Sensing and Geographic Information Systems
9
Changes in vegetation cover refer to variations in the distribution, composition, and overall
structure of plant communities across different temporal and spatial scales. These changes can
occur natural.
PCOS corelations and management through Ayurveda.
This presentation includes basic of PCOS their pathology and treatment and also Ayurveda correlation of PCOS and Ayurvedic line of treatment mentioned in classics.
How to Fix the Import Error in the Odoo 17
An import error occurs when a program fails to import a module or library, disrupting its execution. In languages like Python, this issue arises when the specified module cannot be found or accessed, hindering the program's functionality. Resolving import errors is crucial for maintaining smooth software operation and uninterrupted development processes.
Digital Artifact 1 - 10VCD Environments Unit
Digital Artifact 1 - 10VCD Environments Unit - NGV Pavilion Concept Design
How to Build a Module in Odoo 17 Using the Scaffold Method
Odoo provides an option for creating a module by using a single line command. By using this command the user can make a whole structure of a module. It is very easy for a beginner to make a module. There is no need to make each file manually. This slide will show how to create a module using the scaffold method.
Recently uploaded (20)
Azure Interview Questions and Answers PDF By ScholarHat
Azure Interview Questions and Answers PDF By ScholarHat
Digital Artefact 1 - Tiny Home Environmental Design
Digital Artefact 1 - Tiny Home Environmental Design
ISO/IEC 27001, ISO/IEC 42001, and GDPR: Best Practices for Implementation and...
ISO/IEC 27001, ISO/IEC 42001, and GDPR: Best Practices for Implementation and...
Natural birth techniques - Mrs.Akanksha Trivedi Rama University
Natural birth techniques - Mrs.Akanksha Trivedi Rama University
LAND USE LAND COVER AND NDVI OF MIRZAPUR DISTRICT, UP
LAND USE LAND COVER AND NDVI OF MIRZAPUR DISTRICT, UP
Film vocab for eal 3 students: Australia the movie
Film vocab for eal 3 students: Australia the movie
How to Build a Module in Odoo 17 Using the Scaffold Method
How to Build a Module in Odoo 17 Using the Scaffold Method
Immunotherapy for Parkinson's Disease
- 1. IMMUNOTHERAPY FOR PARKINSON’S DISEASE SAKEEL AHMED (PhD Scholar) Department of Pharmacology (NIPER, Mohali)
- 2. Introduction Parkinson’s disease(PD) is the second most common neurodegenerative disorder in the world, which mainly affect dopaminergic neurons in the substantia nigra pars compacta. People with PD may experience: Resting tremor Bradykinesia Limb Rigidity Postural instability Cognitive changes Constipation Sleep disorders Fatigue Motor symptoms Non-motor symptoms https://www.parkinson.org/Understanding-Parkinsons https://archive.org/stream/manualofdiseases02goweuoft#page/591/mode/1up
- 3. Pathogenesis of Parkinson’s Disease
- 4. Targets for the Immunotherapy
- 5. Figure: Structure of Alpha Synuclein Figure: Pattern of Alpha Synuclein Aggregation β-sheets β-sheets
- 6. Types of Immunotherapy for PD 1. Passive Immunotherapy Antibodies Intrabodies Nanobodies Bispecific Antibody 2. Active Immunotherapy Vaccines
- 7. Challenges in development of Immunotherapy for PD Efficacious active immunization strategies in PD must overcome two rate- limiting obstacles: 1) Specificity for target antigens (αS). 2) Ensure adequate supply of antibodies across the blood-brain barrier (BBB). Others 1) Biomarkers that accurately define subgroups within the PD patient population. 2) Collection, pooling and analyze large scale cohort data by selecting, high quality cohorts.
- 10. Figure. Structure and mechanisms of action of ABL301. ABL301: Bispecific Antibody for PD
- 11. II: :
- 13. Future Prospectus of Immunotherapy for PD Refine predictive models. Develop a biomarker that indicates that the intervention gets to the brain and engages the target. Collect, pooling and analyze large scale cohort data by selecting, high quality cohorts. Incorporate more genetic data in specific subpopulation. Study longitudinal clinical disease-course data and neuropathologic correlation for proposed PD progression patterns. Identify more reliable outcome measure including neuroimaging and wet biomarkers. Develop biomarkers that accurately define subgroups within the PD patient population.
- 14. References 1. Zella, S. M. A. et al. Emerging Immunotherapies for Parkinson Disease. Neurol. Ther. 8, 29– 44 (2019). 2. Mandler, M. et al. Next-generation active immunization approach for synucleinopathies: Implications for Parkinson’s disease clinical trials. Acta Neuropathol. 127, 861–879 (2014). 3. Nishant N.V. et al. Antibodies against alpha-synuclein: Tools and therapy. Neurochemistry, J. O. F. 612–625 (2019). 4. Chatterjee, D. & Kordower, H. Neurobiology of Disease Immunotherapy in Parkinson ’ s disease : Current status and future directions. 132, (2019).
Editor's Notes
- In which there is the lose of the dopaminergic neuron in the SNpc. Postural instability is inability to maintain a steady, upright posture and a decreased blink rate of the eyes, and problems with fine motor coordination (for example, difficulties buttoning a shirt), Bradykinesia and postural instability both contribute to walking—or gait—difficulties. Insomnia like condition and problem in sleep , rapid eye movement (REM) sleep, vivid, bizarre, or disturbing dreams. Fatigue is a term used to describe an overall feeling of tiredness or lack of energy. Cognitive changes problems with thinking, word finding, and judgment are common.
- This peptide includes a cysteine, which is chemically conjugated, through a maleimide molecule, to KLH (keyhole limpet hemocyanin), a strong immunogenic protein. The antigenic complex KLH-peptide was used to stimulate an immunologic response by B cells, but not by T cells, avoiding an autoimmune response